Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.
Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010183&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850074965224718336 |
|---|---|
| author | Catarina E Hioe Guangming Li Xiaomei Liu Ourania Tsahouridis Xiuting He Masaya Funaki Jéromine Klingler Alex F Tang Roya Feyznezhad Daniel W Heindel Xiao-Hong Wang David A Spencer Guangnan Hu Namita Satija Jérémie Prévost Andrés Finzi Ann J Hessell Shixia Wang Shan Lu Benjamin K Chen Susan Zolla-Pazner Chitra Upadhyay Raymond Alvarez Lishan Su |
| author_facet | Catarina E Hioe Guangming Li Xiaomei Liu Ourania Tsahouridis Xiuting He Masaya Funaki Jéromine Klingler Alex F Tang Roya Feyznezhad Daniel W Heindel Xiao-Hong Wang David A Spencer Guangnan Hu Namita Satija Jérémie Prévost Andrés Finzi Ann J Hessell Shixia Wang Shan Lu Benjamin K Chen Susan Zolla-Pazner Chitra Upadhyay Raymond Alvarez Lishan Su |
| author_sort | Catarina E Hioe |
| collection | DOAJ |
| description | Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1 envelope. Antibodies against V3 also were inversely correlated with infection risk in subsets of vaccinees. Antibodies recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined the antiviral potential of poorly neutralizing monoclonal antibodies (mAbs) against immunodominant V1V2 and V3 sites by passive administration of human mAbs to humanized mice engrafted with CD34+ hematopoietic stem cells, followed by mucosal challenge with an HIV-1 infectious molecular clone expressing the envelope of a tier 2 resistant HIV-1 strain. Treatment with anti-V1V2 mAb 2158 or anti-V3 mAb 2219 did not prevent infection, but V3 mAb 2219 displayed a superior potency compared to V1V2 mAb 2158 in reducing virus burden. While these mAbs had no or weak neutralizing activity and elicited undetectable levels of antibody-dependent cellular cytotoxicity (ADCC), V3 mAb 2219 displayed a greater capacity to bind virus- and cell-associated HIV-1 envelope and to mediate antibody-dependent cellular phagocytosis (ADCP) and C1q complement binding as compared to V1V2 mAb 2158. Mutations in the Fc region of 2219 diminished these effector activities in vitro and lessened virus control in humanized mice. These results demonstrate the importance of Fc functions other than ADCC for antibodies without potent neutralizing activity. |
| format | Article |
| id | doaj-art-fd5aefa035fe437aa866a6e470cde8fa |
| institution | DOAJ |
| issn | 1553-7366 1553-7374 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj-art-fd5aefa035fe437aa866a6e470cde8fa2025-08-20T02:46:25ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742022-01-01181e101018310.1371/journal.ppat.1010183Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.Catarina E HioeGuangming LiXiaomei LiuOurania TsahouridisXiuting HeMasaya FunakiJéromine KlinglerAlex F TangRoya FeyznezhadDaniel W HeindelXiao-Hong WangDavid A SpencerGuangnan HuNamita SatijaJérémie PrévostAndrés FinziAnn J HessellShixia WangShan LuBenjamin K ChenSusan Zolla-PaznerChitra UpadhyayRaymond AlvarezLishan SuAntibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1 envelope. Antibodies against V3 also were inversely correlated with infection risk in subsets of vaccinees. Antibodies recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined the antiviral potential of poorly neutralizing monoclonal antibodies (mAbs) against immunodominant V1V2 and V3 sites by passive administration of human mAbs to humanized mice engrafted with CD34+ hematopoietic stem cells, followed by mucosal challenge with an HIV-1 infectious molecular clone expressing the envelope of a tier 2 resistant HIV-1 strain. Treatment with anti-V1V2 mAb 2158 or anti-V3 mAb 2219 did not prevent infection, but V3 mAb 2219 displayed a superior potency compared to V1V2 mAb 2158 in reducing virus burden. While these mAbs had no or weak neutralizing activity and elicited undetectable levels of antibody-dependent cellular cytotoxicity (ADCC), V3 mAb 2219 displayed a greater capacity to bind virus- and cell-associated HIV-1 envelope and to mediate antibody-dependent cellular phagocytosis (ADCP) and C1q complement binding as compared to V1V2 mAb 2158. Mutations in the Fc region of 2219 diminished these effector activities in vitro and lessened virus control in humanized mice. These results demonstrate the importance of Fc functions other than ADCC for antibodies without potent neutralizing activity.https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010183&type=printable |
| spellingShingle | Catarina E Hioe Guangming Li Xiaomei Liu Ourania Tsahouridis Xiuting He Masaya Funaki Jéromine Klingler Alex F Tang Roya Feyznezhad Daniel W Heindel Xiao-Hong Wang David A Spencer Guangnan Hu Namita Satija Jérémie Prévost Andrés Finzi Ann J Hessell Shixia Wang Shan Lu Benjamin K Chen Susan Zolla-Pazner Chitra Upadhyay Raymond Alvarez Lishan Su Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. PLoS Pathogens |
| title | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. |
| title_full | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. |
| title_fullStr | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. |
| title_full_unstemmed | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. |
| title_short | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. |
| title_sort | non neutralizing antibodies targeting the immunogenic regions of hiv 1 envelope reduce mucosal infection and virus burden in humanized mice |
| url | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010183&type=printable |
| work_keys_str_mv | AT catarinaehioe nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT guangmingli nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT xiaomeiliu nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT ouraniatsahouridis nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT xiutinghe nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT masayafunaki nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT jeromineklingler nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT alexftang nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT royafeyznezhad nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT danielwheindel nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT xiaohongwang nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT davidaspencer nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT guangnanhu nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT namitasatija nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT jeremieprevost nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT andresfinzi nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT annjhessell nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT shixiawang nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT shanlu nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT benjaminkchen nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT susanzollapazner nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT chitraupadhyay nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT raymondalvarez nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice AT lishansu nonneutralizingantibodiestargetingtheimmunogenicregionsofhiv1envelopereducemucosalinfectionandvirusburdeninhumanizedmice |